Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Mozobil (plerixafor) Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0089

    Mozobil (plerixafor)

    Customize your policy alerts

    Sign up for Anthem Policy CC-0089 alerts

    Get alerted when Policy CC-0089 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria for use of Mozobil (plerixafor) to mobilize hematopoietic stem cells for autologous (and select allogeneic donor) transplantation and for use during development of ex vivo gene therapy; applies to Anthem medical benefit review and prior authorization. Affects providers requesting Mozobil for eligible patients or donors.

    Policy Summary
    PayerAnthem
    PolicyMozobil (plerixafor) - clinical coverage criteria
    Policy CodePolicy CC-0089
    Change TypeWording/formatting and coding clarifications (annual review)
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date02/20/2027
    Key ActionObtain prior authorization and document indication, concomitant G-CSF or chemo/G-CSF regimen, and planned subsequent autologous transplant (or qualified allogeneic donor scenario).
    SourceLink
    POLICY UPDATE CHANGES

    Wording and formatting criteria updates; coding reviewed and clarification note for billing added; ICD-10-CM C88.9 replaced with C88.90.

    Expanded explicit allowance for use of Mozobil in autologous HSC mobilization as part of development of FDA-approved ex vivo gene therapy (e.g., Zynteglo).

    ≤4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Max injections/ cycle
    up to 2Autologous cycles allowed
    1 cycleAllogeneic insufficient collection
    J2562HCPCS
    Hodgkin/NHL/MM/testicularApplicable diagnoses

    Coverage Criteria for Mozobil (plerixafor)

    Approved Indications / Pathways

    Requests for Mozobil (plerixafor) may be approved if the following criteria are met:

    Age criterion: Individual is under 19 years of age

    Pediatric approval pathway

    Autologous mobilization pathway: Agent is being used to mobilize autologous hematopoietic stem cells AND individual has a diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, testicular carcinoma, or other diagnosis for which autologous HSC transplant is indicated AND after stem cell mobilization and collection a subsequent autologous HSC transplant is anticipated AND the total number of Mozobil (plerixafor) injections has not exceeded four doses per cycle for up to two cycles AND Mozobil is used in combination with one of the following: (A) filgrastim (or biosimilar or tbo-filgrastim) or pegfilgrastim (or biosimilar); OR (B) cyclophosphamide and either filgrastim (or biosimilar or tbo-filgrastim) or sargramostim; OR (C) filgrastim (or biosimilar or tbo-filgrastim) and disease-specific chemotherapy; OR (D) filgrastim (or biosimilar or tbo-filgrastim) or chemo-mobilization following insufficient collection from previous treatment with either alone≤ 4 doses per cycle; up to 2 cycles for autologous

    Meets labeled dosing and NCCN 2A recommended regimens; start after 4 days of filgrastim and administer ~11 hours before apheresis for up to 4 days; weight-based dosing per label

    Allogeneic donor insufficient collection pathway: Individual is an allogeneic donor using Mozobil in combination with filgrastim (or biosimilar or tbo-filgrastim) following insufficient collection from prior filgrastim (or biosimilar or tbo-filgrastim) alone AND the total number of Mozobil (plerixafor) injections has not exceeded four doses per cycle for one cycle≤ 4 doses per cycle; 1 cycle for allogeneic insufficient collection

    Per NCCN guidance

    Gene therapy pathway: Individual is using Mozobil for autologous HSC mobilization as part of development of an FDA-approved ex vivo gene therapy (e.g., Zynteglo)

    Specific allowance for ex vivo gene therapy development

    Requests for Mozobil (plerixafor) may be approved when the following criteria are satisfied: the agent is being used to mobilize hematopoietic stem cells for autologous transplantation or related authorized pathways (including use as part of development of an FDA‑approved ex vivo gene therapy such as Zynteglo), the individual has an appropriate diagnosis (for example lymphoma, multiple myeloma, testicular carcinoma, or other diagnoses for which autologous HSC transplant is indicated), a subsequent autologous HSC transplant is anticipated when applicable, Mozobil is used in combination with an approved mobilization regimen (for example filgrastim/pegfilgrastim or chemotherapy plus growth factor per NCCN/labeling), and dosing/administration limits are respected (see limits below). Prior authorization is required and will be granted only when these documented criteria are met.

    Requests will not be approved when Mozobil is used to mobilize leukemic cells or when the listed clinical criteria are not met. Requests for any other indications beyond those explicitly allowed are also not approved.

    RegimenNotes
    Mozobil (plerixafor) in combination with filgrastim (or biosimilar or tbo‑filgrastim) or pegfilgrastim (or biosimilar)Per labeling and NCCN 2A recommendations: used with daily G‑CSF (filgrastim/pegfilgrastim or biosimilars) for stem cell mobilization prior to apheresis.
    Mozobil in combination with cyclophosphamide plus filgrastim (or biosimilar or tbo‑filgrastim) or sargramostimChemo‑mobilization regimen pairing cyclophosphamide with growth factor as an accepted NCCN 2A combination.
    Mozobil with filgrastim (or biosimilar or tbo‑filgrastim) plus disease‑specific chemotherapyUsed when disease‑specific chemotherapy is part of the mobilization strategy in addition to G‑CSF.
    Mozobil used after insufficient collection with prior growth factor alone (filgrastim/pegfilgrastim or biosimilars) or after chemo‑mobilizationAllowed for allogeneic donors or patients with prior inadequate peripheral stem cell collection; administer in combination with G‑CSF per NCCN guidance.

    Coding and Quantity Limits

    Covered HCPCS/Drug CodeHCPCSCovered
    J2562Injection, plerixafor, 1 mg [Mozobil]
    Relevant ICD-10 Diagnosis CodesICD-10
    C62.00-C62.92Malignant neoplasm of testis
    C81.00-C81.99Hodgkin lymphoma
    C82.00-C88.90Non-Hodgkin lymphomas
    C90.00-C90.32Multiple myeloma and malignant plasma cell neoplasms
    Z52.001Unspecified donor, stem cells
    Z52.011Autologous donor, stem cells
    Z52.091Other blood donor, stem cells
    Z92.86Personal history of gene therapy
    Z94.81Bone marrow transplant status
    Z94.84Stem cells transplant status
    inv-06: Maximum Mozobil injections
    Maximum injections per cycleNo more than 4 injections (doses) of Mozobil (plerixafor) per mobilization cycle.
    Autologous mobilization cycles allowedUp to 2 cycles for autologous hematopoietic stem cell mobilization (total injections per cycle ≤ 4).
    Allogeneic donor insufficient-collection allowance1 cycle permitted for allogeneic donors after insufficient collection with prior filgrastim (total injections per cycle ≤ 4).
    Dose timing relation to apheresisMozobil is administered about 11 hours prior to each apheresis and may be given for up to 4 consecutive days per cycle.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; approval only if documented criteria met

    Prior authorization is required for J2562 (plerixafor). Approval is granted only when documented criteria are met, including age or indication, use for autologous or qualified allogeneic donor scenarios, concomitant G-CSF or chemo/G-CSF regimens per NCCN, and adherence to dose/administration limits and maximum injections per cycle.

    • Covered HCPCS: J2562
    • Approval requires documented planned subsequent autologous HSC transplant when used for autologous mobilization
    • Approval requires adherence to maximum Mozobil injections (≤4 doses per cycle; up to 2 cycles for autologous, 1 cycle for allogeneic insufficient collection)
    Step Therapy

    Combination and step requirements — must be given with specified G-CSF or chemo + growth factor regimens

    Mozobil must be used in combination with specified growth factor or chemo-mobilization regimens per labeling and NCCN (e.g., filgrastim/pegfilgrastim or biosimilars, cyclophosphamide + filgrastim/sargramostim, filgrastim + disease-specific chemotherapy) or following insufficient collection with growth factor alone for donor rescue.

    Regimens and Combinations Covered with Mozobil

    RegimenNotes
    Mozobil (plerixafor) in combination with filgrastim (or biosimilar or tbo‑filgrastim) or pegfilgrastim (or biosimilar)Per labeling and NCCN 2A recommendations: used with daily G‑CSF (filgrastim/pegfilgrastim or biosimilars) for stem cell mobilization prior to apheresis.
    Mozobil in combination with cyclophosphamide plus filgrastim (or biosimilar or tbo‑filgrastim) or sargramostimChemo‑mobilization regimen pairing cyclophosphamide with growth factor as an accepted NCCN 2A combination.
    Mozobil with filgrastim (or biosimilar or tbo‑filgrastim) plus disease‑specific chemotherapyUsed when disease‑specific chemotherapy is part of the mobilization strategy in addition to G‑CSF.
    Mozobil used after insufficient collection with prior growth factor alone (filgrastim/pegfilgrastim or biosimilars) or after chemo‑mobilizationAllowed for allogeneic donors or patients with prior inadequate peripheral stem cell collection; administer in combination with G‑CSF per NCCN guidance.

    Pre-Transplant Mobilization

    pre-transplant mobilization

    Pre-transplant mobilization timing and combination: Mozobil should be started after the individual has received filgrastim once daily for 4 days AND Mozobil should be administered approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days AND Mozobil is used in combination with filgrastim/pegfilgrastim (or biosimilars/tbo-filgrastim) or with chemo + growth factor regimens per NCCNUp to 4 consecutive days; dosing weight-based, not to exceed 40 mg/day

    Timing and dose per product labeling; supports mobilization prior to autologous transplant

    Definitions

    inv-12: Mozobil (plerixafor) — definition/key points
    Drug class and mechanismMozobil (plerixafor) is a CXCR4 (chemokine receptor type 4) inhibitor that mobilizes hematopoietic stem cells from bone marrow into peripheral blood when used with G-CSF.
    Approved combinationApproved in combination with granulocyte colony-stimulating factors (G-CSF) for mobilization of autologous hematopoietic stem cells, primarily for non-Hodgkin lymphoma and multiple myeloma; supported for other indications (e.g., Hodgkin lymphoma, testicular carcinoma).
    Typical use and settingsUsed for autologous HSC mobilization prior to transplant and for donors with insufficient prior collections; also used during development of ex vivo gene therapies (e.g., Zynteglo).
    Dosing overviewWeight-based dosing; given after 4 days of filgrastim; administered ~11 hours before apheresis; available as a 24 mg/1.2 mL vial with maximum dose not to exceed 40 mg/day.

    Background

    Plerixafor (Mozobil) is a CXCR4 (chemokine receptor type 4) inhibitor used in combination with granulocyte‑colony stimulating factor (G‑CSF) to mobilize hematopoietic stem cells into the peripheral blood for collection prior to hematopoietic stem cell transplantation. Labeling and guideline‑based practice support initiating Mozobil after approximately 4 days of filgrastim (or equivalent) and administering the drug about 11 hours before apheresis for up to 4 consecutive days. Use is intended for autologous mobilization (including specified gene‑therapy related collection) and for select allogeneic donor scenarios after insufficient prior collection; dosing must follow the documented per‑cycle limits and combination regimens per NCCN and product labeling.

    Policy Revision History

    2026-02-20Annual reviewLatest

    Wording and formatting criteria updates; coding reviewed with a clarification note for billing and ICD-10-CM code C88.9 replaced with C88.90.

    2025-02-21Annual review

    Annual review completed with no changes to clinical criteria; coding reviewed with no changes.

    2024-02-23Annual review
    Policy Summary
    PayerAnthem
    PolicyMozobil (plerixafor) - clinical coverage criteria
    Policy CodePolicy CC-0089
    Change TypeWording/formatting and coding clarifications (annual review)
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date02/20/2027
    Key ActionObtain prior authorization and document indication, concomitant G-CSF or chemo/G-CSF regimen, and planned subsequent autologous transplant (or qualified allogeneic donor scenario).
    SourceLink
    On This Page
    Coverage Criteria for Mozobil (plerixafor)Coding and Quantity LimitsProvider Requirements, Prior Authorization, and DocumentationRegimens and Combinations Covered with MozobilPre-Transplant MobilizationDefinitionsBackgroundPolicy Revision History
    • Allowed combinations: filgrastim (or biosimilar/tbo-filgrastim) or pegfilgrastim (or biosimilar)
    • Or cyclophosphamide plus filgrastim (or biosimilar/tbo-filgrastim) or sargramostim
    • Or filgrastim plus disease‑specific chemotherapy
    • Or use after insufficient collection from prior growth factor alone (including for allogeneic donors)
    Documentation Required

    Provide supporting diagnosis codes with the request

    Submit diagnosis codes that support the indication; examples listed in the policy include testicular cancer, Hodgkin and non-Hodgkin lymphomas, multiple myeloma, and donor/ transplant history and gene therapy Z-codes.

    • Examples: C62.00-C62.92 (testis malignancy); C81.00-C81.99 (Hodgkin lymphoma); C82.00-C88.90 (non-Hodgkin lymphomas); C90.00-C90.32 (multiple myeloma)
    • Relevant Z-codes: Z52.011 (autologous donor, stem cells), Z52.001 (unspecified donor), Z92.86 (history of gene therapy), Z94.81/Z94.84 (transplant status)
    Denial Risk

    Denial risk: leukemic cell mobilization or failure to meet policy criteria

    Requests will not be approved when Mozobil is used to mobilize leukemic cells or when the policy’s required clinical criteria are not met; requests for all other unlisted indications are also not approved.

    • Not approved when used to mobilize leukemic cells
    • Not approved if the required autologous or allogeneic donor criteria (including combination regimens and maximum injections) are not satisfied

    Added NCCN-recommended combination regimens and allowed use in allogeneic donors for insufficient collection per NCCN; removed 'may not approve' sections regarding allogeneic donors; coding reviewed with no changes.

    2022-09-12Select review

    Expanded criteria to allow use of Mozobil with ex vivo gene therapy; coding updated to add ICD-10-CM Z92.86.

    2019-02-22Annual review

    Updated criteria to include all diagnoses for which autologous hematopoietic stem cell transplant is indicated and updated wording/formatting; coding updated to add ICD-10 codes Z52.001, Z52.011, Z52.091, Z94.81, Z94.84.